Special Offer: Get 50% off your first 2 months when you do one of the following
Personalized offer codes will be given in each session
Name
Paulo Stanga, MD
Title
Consultant Ophthalmologist & Vitreoretinal Surgeon, Retina Lead & Retina Service Partner at London Vision Clinic.
Bio
Specializes in Medical and Surgical Retina: Macular Degeneration, Diabetic Retinopathy, Vitreous Floaters, Cataracts, Advanced Imaging & Clinical Studies. Experience of over 30 years in Ophthalmology and 21 years in the NHS. Left the NHS and the University of Manchester in 2019. Clinical, Surgical and R&D activities at London Vision Clinic, with which he partnered in 2017.
Notable achievements: introduced OCT into clinical setting (UK, 1998), Pascal® Laser (EU, 2006), pioneered Optos® Ultra Wide-Field Imaging (Intl., 2006) & introduced Swept-Source OCT (EU, 2012) as well as Wide-Field OCT (Intl. 2019). Developed the new Hypersonic Vitrectomy technology for Bausch and Lomb Health from lab bench (2012) to FDA 510(k) clearance, First in Human (2017) and EU introduction (2018). Had set-up and was PI and Surgeon for a the first-ever Study of Artificial Vision and the Argus II in Age-Related Macular Degeneration (AMD). Successfully implanted first-ever electronic retinal implants in AMD. Pivotal role for NHS England to fund & evaluate Argus II in Retinitis Pigmentosa (RP) & its 1st use of Artificial (2016). Performed first Argus II implantations in RP in several countries helping set up artificial vision programs with which he continues to collaborate; i.e. Russia. Performed the First-Ever Gene Therapy surgery in the UK in the Independent Sector as part of a clinical study in Geographic Atrophy in Dry AMD (2020). Former UK CI and local Principal Investigator (PI) and Surgeon in a Gene Therapy Study in RP (RPGR); results published in Nature Medicine (2020).
Current Clinical Studies: Gene Therapy Surgery and Anti-Complement Intravitreal Injections in Advanced Dry AMD with Geographic Atrophy, Photo-Biomodulation light-therapy in Early/Intermediate AMD, Laser Ablation of Vitreous Floaters and Management of Vision Degrading Myodesopsia, Wide Field and Navigated OCT and Ultra-Wide Field Vitreo-Retinal Imaging, with several patient recruiting Industry-sponsored or Investigator-initiated Studies.
Actively publishes in peer-reviewed scientific journals with an H-Index of 33.
Received several international accolades, amongst others, the prestigious Achievement Award/American Academy of Ophthalmology (AAO).
Notable achievements: introduced OCT into clinical setting (UK, 1998), Pascal® Laser (EU, 2006), pioneered Optos® Ultra Wide-Field Imaging (Intl., 2006) & introduced Swept-Source OCT (EU, 2012) as well as Wide-Field OCT (Intl. 2019). Developed the new Hypersonic Vitrectomy technology for Bausch and Lomb Health from lab bench (2012) to FDA 510(k) clearance, First in Human (2017) and EU introduction (2018). Had set-up and was PI and Surgeon for a the first-ever Study of Artificial Vision and the Argus II in Age-Related Macular Degeneration (AMD). Successfully implanted first-ever electronic retinal implants in AMD. Pivotal role for NHS England to fund & evaluate Argus II in Retinitis Pigmentosa (RP) & its 1st use of Artificial (2016). Performed first Argus II implantations in RP in several countries helping set up artificial vision programs with which he continues to collaborate; i.e. Russia. Performed the First-Ever Gene Therapy surgery in the UK in the Independent Sector as part of a clinical study in Geographic Atrophy in Dry AMD (2020). Former UK CI and local Principal Investigator (PI) and Surgeon in a Gene Therapy Study in RP (RPGR); results published in Nature Medicine (2020).
Current Clinical Studies: Gene Therapy Surgery and Anti-Complement Intravitreal Injections in Advanced Dry AMD with Geographic Atrophy, Photo-Biomodulation light-therapy in Early/Intermediate AMD, Laser Ablation of Vitreous Floaters and Management of Vision Degrading Myodesopsia, Wide Field and Navigated OCT and Ultra-Wide Field Vitreo-Retinal Imaging, with several patient recruiting Industry-sponsored or Investigator-initiated Studies.
Actively publishes in peer-reviewed scientific journals with an H-Index of 33.
Received several international accolades, amongst others, the prestigious Achievement Award/American Academy of Ophthalmology (AAO).
